BRAF and melanoma: Previous studies also demonstrated that selumetinib and BEZ235 in combination are more effective than these drugs alone on certain BRAF mutant melanoma cell lines (NZM20) [57], in certain lung cancer cell lines (NCI-H1993, NCI-H1975, NCI-H460) [58], or even in patient-derived xenograft models of colorectal carcinomas [69].